StockNews.com Initiates Coverage on Titan Pharmaceuticals (NASDAQ:TTNP)

Posted by on Nov 27th, 2024

Investment analysts at StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a report released on Monday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Trading Up 4.7 %

NASDAQ:TTNP opened at $4.02 on Monday. The stock has a 50-day simple moving average of $4.58 and a 200 day simple moving average of $5.57. Titan Pharmaceuticals has a 52-week low of $3.51 and a 52-week high of $14.80.

Titan Pharmaceuticals Company Profile

(Get Free Report)

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.

Read More

Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.